Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy

Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy

Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neo...

Full description

Bibliographic Details
Main Authors: Cristina Arqueros, Alberto Gallardo, Silvia Vidal, Rubén Osuna-Gómez, Ariadna Tibau, Olga Lidia Bell, Teresa Ramón y Cajal, Enrique Lerma, Bárbara Lobato-Delgado, Juliana Salazar, Agustí Barnadas
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:International Journal of Molecular Sciences
Subjects:
breast cancer
neoadjuvant chemotherapy
stromal tumour-infiltrating lymphocytes
tumour-infiltrating immune cells
Online Access:https://www.mdpi.com/1422-0067/25/5/2627

Internet

https://www.mdpi.com/1422-0067/25/5/2627

Similar Items